Sign in

Private company

Genfit S.A.

Genfit S.A. is a biological products company.1

Last updated Oct 21, 2026.

Overview

70.9MRevenue, fiscal 20242
1.5MNet income, fiscal 20242
  • IndustryBiological Products, (No Diagnostic Substances)1
  • HeadquartersI01
  • Incorporated inFrance3
  • Business addressParc Eurasante, 885, Avenue Eugene Avinee, Loos, I0 591203
  • Filer categoryAccelerated filer3

See how the biggest companies compare on our leaderboards

GENFIT is a biopharmaceutical group conducting preclinical and clinical research and development of drug candidates and diagnostic technologies and dedicated to improving the lives of patients with liver diseases with high unmet medical needs, with a special focus on rare, life-threatening and acute pathologies. Our legal name is "GENFIT SA," or a French société anonyme, and our principal executive office is located at Parc Eurasanté 885, avenue Eugène Avinée 59120 Loos, France. Our telephone number at our principal executive office is +33 (0)3 2016 4000. Our agent for service of process in the United States is Corporation Service Company, located at 19 West 44th Street, Suite 200, New York, NY 10036.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from. Figures are in EUR, the currency the company reports in.

Key numbers, fiscal 2024

4.6%Operating margin2
2.1%Net margin2
85.8%Revenue growth, 20242
2.2%Return on equity2
14.6M EURFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Research and development67¢47.2M EUR
  • Other costs24¢17.2M EUR
  • Interest7¢4.7M EUR
  • Income tax0¢340.0K EUR
  • Profit2¢1.5M EUR

Out of 70.9M EUR in revenue.2

Where each dollar of operating cash went, fiscal 2024

  • Capital spending6¢979.0K EUR
  • Kept or used elsewhere94¢14.6M EUR

Out of 15.5M EUR of cash from operations.2

Financial statements

Revenue56789270.9M EUR in 2024+935% since 2017
025.0M EUR50.0M EUR75.0M EUR100.0M EUR2017: 6.9M EUR6.9M EUR20172018: 7.5M EUR7.5M EUR2018+9%2019: 41.0M EUR41.0M EUR2019+447%2020: 7.8M EUR7.8M EUR2020−81%2021: 85.6M EUR85.6M EUR2021+1003%2022: 26.6M EUR26.6M EUR2022−69%2023: 38.2M EUR38.2M EUR2023+44%2024: 70.9M EUR70.9M EUR2024+86%
Operating income5678923.3M EUR in 2024
-100.0M EUR-50.0M EUR050.0M EUR2017: -56.7M EUR-56.7M EUR20172018: -69.5M EUR-69.5M EUR2018+23%2019: -57.8M EUR-57.8M EUR2019−17%2020: -82.9M EUR-82.9M EUR2020+43%2021: 31.8M EUR31.8M EUR20212022: -27.3M EUR-27.3M EUR20222023: -26.6M EUR-26.6M EUR2023−3%2024: 3.3M EUR3.3M EUR2024
Net income5678921.5M EUR in 2024
-150.0M EUR-100.0M EUR-50.0M EUR050.0M EUR100.0M EUR2017: -55.7M EUR-55.7M EUR20172018: -79.5M EUR-79.5M EUR2018+43%2019: -65.1M EUR-65.1M EUR2019−18%2020: -101.2M EUR-101.2M EUR2020+55%2021: 67.3M EUR67.3M EUR20212022: -23.7M EUR-23.7M EUR20222023: -28.9M EUR-28.9M EUR2023+22%2024: 1.5M EUR1.5M EUR2024
Fiscal year20172018201920202021202220232024
Revenue6.9M EUR57.5M EUR641.0M EUR77.8M EUR885.6M EUR926.6M EUR238.2M EUR270.9M EUR2
Research and development35.2M EUR935.8M EUR246.5M EUR247.2M EUR2
Operating income-56.7M EUR5-69.5M EUR6-57.8M EUR7-82.9M EUR831.8M EUR9-27.3M EUR2-26.6M EUR23.3M EUR2
Interest4.8M EUR94.3M EUR24.6M EUR24.7M EUR2
Income before tax69.5M EUR9-23.8M EUR2-28.5M EUR21.8M EUR2
Income tax2.2M EUR9-116.0K EUR2380.0K EUR2340.0K EUR2
Net income-55.7M EUR5-79.5M EUR6-65.1M EUR7-101.2M EUR867.3M EUR9-23.7M EUR2-28.9M EUR21.5M EUR2
Earnings per share-2 EUR/shares7-3 EUR/shares82 EUR/shares9-0 EUR/shares2-1 EUR/shares20 EUR/shares2
Earnings per share (diluted)-2 EUR/shares7-3 EUR/shares81 EUR/shares9-0 EUR/shares2-1 EUR/shares20 EUR/shares2
Shares (weighted, basic)44.7B shares949.7B shares249.7B shares249.8B shares2
Shares (weighted, diluted)55.6B shares949.7B shares249.7B shares249.9B shares2

Compare Genfit S.A. with another company

Corporate structure

Genfit S.A. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Genfit S.A.

  • Genfit S.A. I0

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Genfit S.A. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net7.6M EUR2 Dec 31, 20247.9M EUR2 Dec 31, 2023−3.5%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)48.0M EUR2 Dec 31, 202448.8M EUR2 Dec 31, 2023−1.6%

Inventory

ItemLatestA year beforeChange
Inventory, total4.0K EUR2 Dec 31, 20244.0K EUR2 Dec 31, 20230%

Filings

112 filings to the SEC since October 2021: 4 annual reports, 3 large holders, 105 other. The latest 20:

  1. Nov 20, 202515F-12B EDGAR
  2. Nov 14, 2025S-8 POS EDGAR
  3. Nov 14, 2025RW EDGAR
  4. Nov 10, 202525 EDGAR
  5. Nov 10, 20256-K EDGAR
  6. Nov 10, 20256-K EDGAR
  7. Oct 30, 20256-K EDGAR
  8. Oct 28, 20256-K EDGAR
  9. Sep 22, 20256-K EDGAR
  10. Sep 22, 20256-K EDGAR
  11. Sep 19, 20256-K EDGAR
  12. Jul 8, 20256-K EDGAR
  13. Jun 17, 20256-K EDGAR
  14. May 22, 20256-K EDGAR
  15. May 20, 20256-K EDGAR
  16. May 14, 20256-K EDGAR
  17. May 7, 20256-K EDGAR
  18. May 5, 20256-K EDGAR
  19. Apr 29, 202520-F EDGAR
  20. Apr 29, 20256-K EDGAR

The 112 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Genfit S.A. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGenfit S.A.1
  • CIK0001757064
  • Filer statusAccelerated filer not an emerging growth company; not a shell company4
  • Incorporated inFrance4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressParc Eurasante, 885, Avenue Eugene Avinee, Loos, I0 591201
  • Phone33 3 20 16 40001
  • Shares outstanding49,996,185 shares as of Dec 31, 20244
  • AuditorErnst & Young et Autres, Paris, France PCAOB ID 1704; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceNov 16, 20181
  • Filings210 in all: 6-K (169), 20-F (6), CORRESP (5), UPLOAD (5), DRS/A (3), DRSLTR (2), EFFECT (2), SC 13G (2)1
    All 23 form types

    SC 13G/A (2), 15F-12B (1), 25 (1), 424B4 (1), 6-K/A (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1/A (1), F-1MEF (1), F-3 (1), RW (1), S-8 (1), S-8 POS (1)

  • Latest filingsAnnual report (20-F) Apr 29, 2025

Securities registered for trading

ClassSymbolExchange
American Depositary Shares, each representing one ordinary share, nominal value €0.25 per shareGNFTThe Nasdaq Global Select Market

From the cover page of the 20-F filed Apr 29, 2025 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11